SCHEMBL6946295

SCHEMBL6946295

Clc1nc(Cc2ccc3c(c2)OCO3)ncc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.50
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAOA P21397 4/20 0.43
ADORA1 P30542 1/20 0.41
PDE5A O76074 2/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
POLB P06746 2/20 0.40
GFER P55789 1/20 0.39
KDM4E B2RXH2 2/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CALM1 P0DP23 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6943260 0.88 MAOB (0.51) MAOBKMT2ATDP1L3MBTL1MAOA
SCHEMBL6945047 0.86 MAOB (0.54) MAOBKMT2ATDP1L3MBTL1MAOA
SCHEMBL6944820 0.84 PDE5A (0.47) KMT2ATDP1L3MBTL1PDE5AALDH1A1
SCHEMBL6943670 0.79 SMN1; SMN2 (0.42) KMT2ATDP1PDE5ANPC1RAB9A
SCHEMBL6946706 0.77 ALDH1A1 (0.44) POLBKDM4EHTTALDH1A1
SCHEMBL6944322 0.76 MAOB (0.53) MAOBKMT2ATDP1L3MBTL1MAOA
SCHEMBL6947146 0.75 SMN1; SMN2 (0.49) KMT2ATDP1L3MBTL1RAB9APOLB
SCHEMBL6942798 0.74 NOS2 (0.54) MAOBMAOA
SCHEMBL6944624 0.72 SMN1; SMN2 (0.49) KMT2APOLBKDM4EHTTALDH1A1
SCHEMBL6939898 0.72 GAA (0.49) KMT2APDE5AALDH1A1CALM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
EP-1268471-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-02 EP disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed
WO-2001072744-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 MAOB 18/4885KMT2A 2660/4885TDP1 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.